Food intolerance and diagnostics company Omega Diagnostics has gained an order for VISITECT CD4 advanced disease from Zimbabwe.
Unlike the previous Nigerian order, this is not dependent on any approvals. The order is worth £80,000 (for 20,000 units) and it is not being sold to NGOs. The advanced disease test got its CE mark in March 2019 and it is being reviewed by UNITAID and then, if approved, it can be sold to NGOs.
The share price has perked up since the announcement and is 10.25p.
© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Omega Diagnostics will lose money this year, but it is on course to become profitable in 2020-21 as sales of the VISITECT CD4 test.
House broker Shore Capital has slashed its pre-tax profit forecast for engineer Tricorn Group by two-thirds to £420,000.
Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment.